Semax
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
What is it?
Semax is the Russian-developed nootropic peptide that does something most cognitive enhancers can’t: it sharpens focus and clears mental fog without acting as a stimulant. No racing heart, no blood-pressure spike, no jittery edge. Users describe themselves as more clear, not more wired. That single feature — clarity without stimulation — is why Semax has become the peptide of choice for people burned out on caffeine, Adderall, and modafinil.
Structurally, Semax is a synthetic heptapeptide: a seven-amino-acid fragment of ACTH (adrenocorticotropic hormone), with a stabilizing Pro-Gly-Pro tail tacked on so it survives long enough to do its job. It was developed at the Russian Academy of Sciences and is approved in Russia for stroke recovery, traumatic brain injury, and a range of cognitive/vascular conditions. In the US it’s a research chemical — accessible, not approved.
What’s distinctive about Semax mechanistically is that it doesn’t push the brain harder (the stimulant model). It rebuilds the substrate. Through direct transcriptional upregulation of BDNF and NGF — the two best-characterized neurotrophic growth factors — Semax acts as a construction signal. The clarity isn’t a temporary effect of forced neurotransmitter release; it’s downstream of better, more plastic, better-fueled neurons.
What does it do in my body?
Semax binds MC4 and MC3 melanocortin receptors in the hippocampus and prefrontal cortex — the same MC4 receptor family that PT-141 (bremelanotide) acts on, interestingly, but in a completely different brain region. From there, several mechanisms work together:
Direct transcriptional upregulation of BDNF and NGF. BDNF (brain-derived neurotrophic factor) is the brain’s repair, plasticity, and learning signal; NGF (nerve growth factor) protects and extends neurons. One practitioner’s framing: Semax “flips the DNA switch labeled ‘build more brain’ to ON.” This is what separates Semax from classic nootropics — caffeine, racetams, modafinil push existing systems; Semax tells the genome to upregulate the neurotrophic machinery itself.
Adult neurogenesis. Via cAMP and downstream transcription factors, Semax appears to push neural stem cells in the dentate gyrus to differentiate into integrated, functional neurons — not just protect existing ones.
Dopaminergic + serotonergic modulation. Semax modulates dopamine and serotonin pathways at the level of synthesis and signaling rather than as a reuptake inhibitor or releaser. This is the mechanistic basis for the “motivation + drive” effects users report — without the crash, the tolerance, or the side-effect class of amphetamines.
Three-failures framework: applied to the brain. One practitioner maps Semax onto the same three-failure structure he uses for mitochondrial dysfunction (see MOTS-c):
| Brain “failure” | Mechanism | Semax’s lever |
|---|---|---|
| 1. Inflammatory firestorm | BBB cytokine flood (IL-1β, TNF-α, IL-6) → disrupts synaptic plasticity, inhibits LTP, drives neuronal apoptosis | Modulates NF-κB → reduces pro-inflammatory cytokines |
| 2. Energy famine | Insulin resistance → neurons starve (Alzheimer’s increasingly reframed as “Type 3 diabetes”) (de la Monte literature) | Enhances brain GLUT expression + insulin signaling → forces glucose into starving neurons |
| 3. Power-plant meltdown | Mitochondrial dysfunction → ROS up, ATP down | Upregulates PGC1-α mitochondrial biogenesis + enhances glutathione production (see Glutathione) |
On the BBB-crossing question (intranasal route). There’s a real debate in the practitioner community about whether nasal-spray peptides reach the brain at all. The honest answer is per-peptide. For Semax specifically, intranasal is the validated clinical route: it’s what the decades of Russian clinical use are built on, and it’s what clinics using Semax today (Durst’s RevitalizeMD, others) deliver. Other peptides with documented intranasal CNS uptake — insulin, oxytocin — show the route works for the right molecules. Semax has the right physicochemical profile (small, polar, with documented olfactory-pathway uptake) quantitative bioavailability.
Route changes which effect dominates — Semax shows the same route-dependent receptor dichotomy as Selank. Andreeva et al. 2020 in Neurochemical Journal (“Predominance of Nootropic or Anxiolytic Effects of Selank, Semax, and Noopept Peptides Depending on the Route of Administration”) tested all three peptides on both intranasal and intraperitoneal routes in BALB/c and C57BL/6 mice. The pattern: intranasal Semax produces predominantly nootropic effects (focus / learning / cognitive output — what most Semax users are after) while intraperitoneal/injectable Semax shifts toward predominantly anxiolytic effects. The same molecule on two routes engages different downstream brain systems. The mechanistic underpinning extends across both peptides — Selank shows the same pattern with different receptor specifics (intranasal Selank → NMDA receptor engagement; intraperitoneal Selank → GABA receptor engagement, +38% vs +23% binding changes per Volkova 2018 PMID 29787664). See the detailed treatment in Selank under “Route changes the receptor — intranasal vs injectable” for the full mechanism + protocol implications. For Semax specifically: stick with intranasal if you want the nootropic / focus / learning effect that the entire published Russian clinical record is built on. Injectable Semax is plausibly useful for an anxiolytic-shifted profile, but that’s a different use case from what most readers come to Semax for.
How can it help me?
- Best fit: Cognitive fog, attention/focus deficits, high-demand mental work, neuroprotection during stress; people who want clarity without the wired feel of stimulants
- Where the science stands: Decades of Russian clinical use (stroke, TBI, vascular cognitive disorders) + animal/preclinical mechanism work; minimal Western RCTs
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
Semax is well-tolerated in the published clinical use record. The real-world side-effect cluster:
- Nasal irritation / transient dryness — the most common AE, from the spray vehicle. Usually minor; rotate nostrils, hydrate the nasal mucosa.
- Mild headache at higher doses or first few days; typically resolves.
- Sleep disturbance if dosed too late in the day — Semax is activating. Keep dosing to morning/early afternoon.
- Elevated baseline anxiety in a subset of sensitive users at higher doses — this is the Semax-vs-Selank decision point: if you tend toward anxious/wired baseline, Selank is the better starting tool.
- Transient blood-pressure changes documented in some Russian reports; clinically usually trivial but worth noting if you’re hypertensive.
There’s no documented dependence, tolerance, or withdrawal pattern — Semax is not a stimulant in the pharmacological sense, and the protocol design (4 weeks on / 2 weeks off) reflects receptor-pharmacology caution, not a withdrawal-management concern.
Regulatory status: Russia: Approved by the Russian Ministry of Health for stroke recovery, TBI, and cognitive/vascular disorders. Sold commercially as 0.1% and 1% intranasal solutions. US: Not FDA-approved for any indication. Not a controlled substance. Sold legally as a research chemical, “not for human consumption.” Not on the WADA prohibited list (which is unusual for a peptide of this profile and notable for athletes). NOT available via 503A compounding pharmacies: on September 29, 2023, FDA added Semax (heptapeptide) to its Category 2 bulk-drug-substances list — substances flagged with significant-safety-concern questions, which bars them from 503A compounding. (Selank acetate and DSIP/Emideltide were added in the same action.) So unlike the BPC-157-era “available via compounding” framing, Semax is research-channel-only in the US. This is an active regulatory area tied to the FDA’s pharmacy-compounding advisory agenda.
Part 1 — How to reconstitute it
What's used: bacteriostatic water (sterile, preserved water the powder is mixed with) and a separate, larger reconstitution syringe used only for mixing — not the small syringe used for administration.
Reconstitution + concentration math. Semax is sold either as a pre-made nasal spray (0.1% = 1 mg/mL or 1% = 10 mg/mL) or as a lyophilized powder reconstituted into a metered nasal-spray bottle. The standard pharmaceutical spray dispenses ~0.05 mL per actuation; at 1 mg/mL that’s 50 mcg per spray, and at 10 mg/mL that’s 500 mcg per spray. exact metered-dose volume across common compounded products.
The clean DIY nasal-spray recipe (added 2026-06-22): for users reconstituting their own from a lyophilized vial using a generic metered-dose nasal sprayer (which dispenses ~0.1 mL per actuation, larger than the pharmaceutical 0.05 mL standard), the most-elegant arrangement is 10 mg vial + 5 mL sterile saline → 2 mg/mL → ~0.1 mL per spray = 200 mcg per spray (5 mL bottle ≈ 50 sprays). The standard low/mid/high tier becomes a clean 1 / 2 / 3 sprays = 200 / 400 / 600 mcg. This protocol applies identically to Selank — see Selank for the full sterile-saline-vs-bacteriostatic-water trade-off discussion (sterile saline preferred for daily intranasal use because BAC water’s benzyl alcohol is mucosa-irritating with cumulative exposure; trade-off is no preservative = refrigerate + use within 7-14 days vs 28+ day BAC vial life). Boil generic aftermarket nasal sprayer bottles before first use — they’re NOT shipped sterile.
How it's mixed
- The vial is tilted and the bacteriostatic water is added slowly down the inside glass wall — not squirted straight onto the powder.
- It is swirled gently to dissolve. It is never shaken — shaking can damage the peptide.
- The reconstituted vial is stored refrigerated and out of light.
- Reconstituted peptides are commonly used within a few weeks, inside the beyond-use window the source specifies — that window varies by peptide.
The free reconstitution calculator does the concentration math for any vial size and water volume, including the equivalent units on an insulin syringe.
Part 2 — Typical dosing
Educational context only — talk to a licensed medical provider before any protocol. What follows describes the doses and schedules most commonly reported in the research and by practitioners, shared so you can have an informed conversation. These compounds are sold for research use only, are not FDA-approved drugs, and this is not medical advice.
Administration as reported. Reported practice is subcutaneous administration (into the fat just under the skin) using a 0.3 mL U-100 insulin syringe, with sites rotated.
Route. Intranasal spray is the standard. Subcutaneous is occasionally used but isn’t the validated clinical route — stick with intranasal.
Community-standard protocol (converged across Russian clinical use + practitioner reports):
- Standard cognitive dose: 300-600 mcg/day, split into 2-3 administrations (one spray per nostril per dose).
- Higher-end / acute neuroprotection dose: up to 1,000-1,200 mcg/day for 7-14 days (the dosage Russian clinical use targets for stroke/TBI recovery).
- Timing: Morning + early afternoon. Avoid evening dosing — Semax’s activating effect can interfere with sleep onset for some users.
- Cycle: one practitioner’s clinic protocol is 4 weeks on / 2 weeks off to prevent MC4/MC3 receptor downregulation. Many users run shorter on/off blocks (10-14 on / 7-10 off) per the Selank-style pattern.
Turning milligrams into syringe units. On a U-100 syringe, 100 units = 1 mL, so 1 unit = 0.01 mL. At a concentration of C mg/mL, a dose of D mg = D ÷ C mL = (D ÷ C) × 100 units. Example: at 5 mg/mL, a 0.5 mg dose = 0.1 mL = 10 units. The exact units depend on the vial's mg and the water volume used.
What should I avoid combining — and what's synergistic?
Stacking. The natural pair is Semax + Selank: Semax activates and clarifies, Selank calms and stabilizes. Russian clinical use sometimes co-administers them at lower doses (100 mcg Semax + 100-200 mcg Selank intranasal) for mixed cognitive-anxiety presentations — no controlled trial validates the combination specifically, so trial each individually first. For cognitive-decline support, one practitioner’s broader “Unleash Hell” stack pairs Semax with BPC-157 (gut/systemic anti-inflammatory), GHK-Cu (multi-gene cellular repair signal), alpha-GPC (choline precursor), and Cerebrolysin where available.
Where do people source this?
A physician-prescribed route exists for Semax. Semax, as a semax + selank combination, is available through licensed US telehealth providers: an online intake, review by a licensed physician, and — if prescribed — compounding at a licensed 503A/503B pharmacy with delivery to the door. See the prescribed Semax option →
OHM does not sell or handle any compound. Research-use-only material is also sold by third-party vendors; our vetting notes and disclosures are on the Where to buy page. Whatever the route, the supply chain is the real risk: only consider sources that publish batch-level third-party Certificates of Analysis.
| Class | Synthetic heptapeptide; fragment of ACTH(4-7) with a Pro-Gly-Pro tail (Met-Glu-His-Phe-Pro-Gly-Pro) exact sequence |
| Mechanism (one line) | MC4/MC3 melanocortin-receptor agonist in hippocampus + prefrontal cortex → direct transcriptional upregulation of BDNF and NGF → neuroplasticity + neurogenesis |
| Route / frequency | Intranasal spray (the validated clinical route in Russian use); 1-3× daily |
| Half-life | Short in plasma; CNS effect persists hours after a single intranasal dose |
| Evidence base | Decades of Russian clinical use (stroke, TBI, vascular cognitive disorders) + animal/preclinical mechanism work; minimal Western RCTs |
| Safety record | Favorable; mild AEs commonly reported (transient nasal irritation, occasional headache); the “zero AEs ever” framing is overstated |
| Regulatory status | Russia: approved (stroke / cognitive indications). US: not FDA-approved; sold as a research chemical |
| Best-fit user | Cognitive fog, attention/focus deficits, high-demand mental work, neuroprotection during stress; people who want clarity without the wired feel of stimulants |
What it is
Semax is the Russian-developed nootropic peptide that does something most cognitive enhancers can’t: it sharpens focus and clears mental fog without acting as a stimulant. No racing heart, no blood-pressure spike, no jittery edge. Users describe themselves as more clear, not more wired. That single feature — clarity without stimulation — is why Semax has become the peptide of choice for people burned out on caffeine, Adderall, and modafinil.
Structurally, Semax is a synthetic heptapeptide: a seven-amino-acid fragment of ACTH (adrenocorticotropic hormone), with a stabilizing Pro-Gly-Pro tail tacked on so it survives long enough to do its job. It was developed at the Russian Academy of Sciences and is approved in Russia for stroke recovery, traumatic brain injury, and a range of cognitive/vascular conditions. In the US it’s a research chemical — accessible, not approved.
What’s distinctive about Semax mechanistically is that it doesn’t push the brain harder (the stimulant model). It rebuilds the substrate. Through direct transcriptional upregulation of BDNF and NGF — the two best-characterized neurotrophic growth factors — Semax acts as a construction signal. The clarity isn’t a temporary effect of forced neurotransmitter release; it’s downstream of better, more plastic, better-fueled neurons.
How it works
Semax binds MC4 and MC3 melanocortin receptors in the hippocampus and prefrontal cortex — the same MC4 receptor family that PT-141 (bremelanotide) acts on, interestingly, but in a completely different brain region. From there, several mechanisms work together:
Direct transcriptional upregulation of BDNF and NGF. BDNF (brain-derived neurotrophic factor) is the brain’s repair, plasticity, and learning signal; NGF (nerve growth factor) protects and extends neurons. One practitioner’s framing: Semax “flips the DNA switch labeled ‘build more brain’ to ON.” This is what separates Semax from classic nootropics — caffeine, racetams, modafinil push existing systems; Semax tells the genome to upregulate the neurotrophic machinery itself.
Adult neurogenesis. Via cAMP and downstream transcription factors, Semax appears to push neural stem cells in the dentate gyrus to differentiate into integrated, functional neurons — not just protect existing ones.
Dopaminergic + serotonergic modulation. Semax modulates dopamine and serotonin pathways at the level of synthesis and signaling rather than as a reuptake inhibitor or releaser. This is the mechanistic basis for the “motivation + drive” effects users report — without the crash, the tolerance, or the side-effect class of amphetamines.
Three-failures framework: applied to the brain. One practitioner maps Semax onto the same three-failure structure he uses for mitochondrial dysfunction (see MOTS-c):
| Brain “failure” | Mechanism | Semax’s lever |
|---|---|---|
| 1. Inflammatory firestorm | BBB cytokine flood (IL-1β, TNF-α, IL-6) → disrupts synaptic plasticity, inhibits LTP, drives neuronal apoptosis | Modulates NF-κB → reduces pro-inflammatory cytokines |
| 2. Energy famine | Insulin resistance → neurons starve (Alzheimer’s increasingly reframed as “Type 3 diabetes”) (de la Monte literature) | Enhances brain GLUT expression + insulin signaling → forces glucose into starving neurons |
| 3. Power-plant meltdown | Mitochondrial dysfunction → ROS up, ATP down | Upregulates PGC1-α mitochondrial biogenesis + enhances glutathione production (see Glutathione) |
On the BBB-crossing question (intranasal route). There’s a real debate in the practitioner community about whether nasal-spray peptides reach the brain at all. The honest answer is per-peptide. For Semax specifically, intranasal is the validated clinical route: it’s what the decades of Russian clinical use are built on, and it’s what clinics using Semax today (Durst’s RevitalizeMD, others) deliver. Other peptides with documented intranasal CNS uptake — insulin, oxytocin — show the route works for the right molecules. Semax has the right physicochemical profile (small, polar, with documented olfactory-pathway uptake) quantitative bioavailability.
Route changes which effect dominates — Semax shows the same route-dependent receptor dichotomy as Selank. Andreeva et al. 2020 in Neurochemical Journal (“Predominance of Nootropic or Anxiolytic Effects of Selank, Semax, and Noopept Peptides Depending on the Route of Administration”) tested all three peptides on both intranasal and intraperitoneal routes in BALB/c and C57BL/6 mice. The pattern: intranasal Semax produces predominantly nootropic effects (focus / learning / cognitive output — what most Semax users are after) while intraperitoneal/injectable Semax shifts toward predominantly anxiolytic effects. The same molecule on two routes engages different downstream brain systems. The mechanistic underpinning extends across both peptides — Selank shows the same pattern with different receptor specifics (intranasal Selank → NMDA receptor engagement; intraperitoneal Selank → GABA receptor engagement, +38% vs +23% binding changes per Volkova 2018 PMID 29787664). See the detailed treatment in Selank under “Route changes the receptor — intranasal vs injectable” for the full mechanism + protocol implications. For Semax specifically: stick with intranasal if you want the nootropic / focus / learning effect that the entire published Russian clinical record is built on. Injectable Semax is plausibly useful for an anxiolytic-shifted profile, but that’s a different use case from what most readers come to Semax for.
What the research shows
Russian clinical record: first-class evidence, even if it’s not on PubMed in English. Semax has been used clinically in Russia since the 1990s for:
- Acute ischemic stroke — Gusev, Skvortsova et al. 1997 reported improved neurological recovery in acute ischemic stroke at 12–18 mg/day (PMID 11517472); Gusev, Martynov et al. 2018 found Semax raised plasma BDNF and improved motor recovery and functional outcomes over a 20-day course (PMID 29798983).
- Cerebrovascular insufficiency — Gusev, Skvortsova, Chukanova 2005 (n=187): Semax stabilized progression and reduced stroke/TIA risk (PMID 15792140).
- Cognitive/connectivity effects (modern fMRI) — Lebedeva, Panikratova et al. 2018 (n=24): Semax increased default-mode-network volume in medial frontal cortex vs. placebo (PMID 30225715); Panikratova et al. 2020 (n=52): Semax and Selank produce distinct amygdala/prefrontal connectivity changes (PMID 32342318).
- Optic-nerve / vascular optic neuropathy (Russian indication) — Polunin et al. 2000 (PMID 10741256); Dragon et al. 2022 (n=60) combined neurostimulation + Semax improved visual field/light sensitivity (PMID 36083821).
- Refractory peptic ulcer (an off-target but documented use) — Ivanikov et al. 2002: 89.5% healing vs 30.8% control (PMID 12459874).
Russian regulatory approval requires a clinical evidence package; the published literature exists but is largely in Russian-language journals not fully indexed in PubMed. (Note: several Semax PMIDs circulating on aggregator sites are mis-scraped — e.g. papers on LDL cholesterol and thyroid elastography that have nothing to do with Semax — so verify any Semax citation against the actual abstract before customer-facing use.) One practitioner’s “decades of clinical use, zero adverse events” framing is the kind of overstatement that doesn’t survive scrutiny — published adverse events do exist (mostly minor: nasal irritation, transient blood-pressure changes, headache). But the clean safety story over decades of routine clinical use — that’s real.
Animal / preclinical: first-class evidence, and this is where Semax’s mechanism is best documented.
- Ischemia / stroke models (rat) — Semax reduces infarct size and improves functional recovery in MCAO (middle cerebral artery occlusion) models; mechanism attributed to BDNF upregulation + anti-inflammatory cytokine shift.
- Cognitive performance + neurogenesis (rat) — Improvement in learning/memory tasks; increased BDNF/NGF expression in hippocampus + prefrontal cortex; markers of adult neurogenesis upregulated.
- Parkinson’s models: Semax upregulates tyrosine hydroxylase (the rate-limiting enzyme for dopamine synthesis) and protects dopaminergic neurons in the substantia nigra against mitochondrial toxins.
- Multiple sclerosis / demyelination models — Shifts the cytokine profile from TH1/TH17 toward TH2/T-reg (immune re-education, not suppression); promotes oligodendrocyte progenitor cell differentiation → myelin rebuild.
The Alzheimer’s reframe. One practitioner’s editorial position: and increasingly the position of a chunk of the Alzheimer’s research community — is that amyloid plaques and tau tangles are symptoms, not the cause. The real upstream problem: microglial failure to clear debris, chronic neuroinflammation, and metabolic (insulin) dysfunction in the brain. The “Alzheimer’s as Type 3 diabetes” reframe (de la Monte et al.) is published, well-cited, and worth knowing about. Semax addresses this stack — anti-inflammatory, pro-glucose-utilization, neurotrophic — which is the mechanistic case for it as a candidate cognitive-decline intervention. The clinical proof in Alzheimer’s specifically is still preliminary; the mechanism is rational and the Russian use record is suggestive.
Where experts read it differently. One practitioner treats the Russian clinical record as essentially conclusive evidence of broad efficacy across cognitive decline, stroke recovery, and neuroprotection — and dismisses nasal-spray delivery broadly (a broad dismissal that doesn’t hold up against Semax’s actual clinical use). Durst takes the clinical-use record at face value and treats intranasal as the standard route — which matches the actual evidence. The honest read: Semax has a real, decades-long clinical track record in one country, a mechanistically rational case for its effects, and an active preclinical literature; the absence of Western RCTs is a gap in the evidence map, not evidence of absence.
Real-world protocol
The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.
Route. Intranasal spray is the standard. Subcutaneous is occasionally used but isn’t the validated clinical route — stick with intranasal.
Reconstitution + concentration math. Semax is sold either as a pre-made nasal spray (0.1% = 1 mg/mL or 1% = 10 mg/mL) or as a lyophilized powder reconstituted into a metered nasal-spray bottle. The standard pharmaceutical spray dispenses ~0.05 mL per actuation; at 1 mg/mL that’s 50 mcg per spray, and at 10 mg/mL that’s 500 mcg per spray. exact metered-dose volume across common compounded products.
The clean DIY nasal-spray recipe (added 2026-06-22): for users reconstituting their own from a lyophilized vial using a generic metered-dose nasal sprayer (which dispenses ~0.1 mL per actuation, larger than the pharmaceutical 0.05 mL standard), the most-elegant arrangement is 10 mg vial + 5 mL sterile saline → 2 mg/mL → ~0.1 mL per spray = 200 mcg per spray (5 mL bottle ≈ 50 sprays). The standard low/mid/high tier becomes a clean 1 / 2 / 3 sprays = 200 / 400 / 600 mcg. This protocol applies identically to Selank — see Selank for the full sterile-saline-vs-bacteriostatic-water trade-off discussion (sterile saline preferred for daily intranasal use because BAC water’s benzyl alcohol is mucosa-irritating with cumulative exposure; trade-off is no preservative = refrigerate + use within 7-14 days vs 28+ day BAC vial life). Boil generic aftermarket nasal sprayer bottles before first use — they’re NOT shipped sterile.
Community-standard protocol (converged across Russian clinical use + practitioner reports):
- Standard cognitive dose: 300-600 mcg/day, split into 2-3 administrations (one spray per nostril per dose).
- Higher-end / acute neuroprotection dose: up to 1,000-1,200 mcg/day for 7-14 days (the dosage Russian clinical use targets for stroke/TBI recovery).
- Timing: Morning + early afternoon. Avoid evening dosing — Semax’s activating effect can interfere with sleep onset for some users.
- Cycle: one practitioner’s clinic protocol is 4 weeks on / 2 weeks off to prevent MC4/MC3 receptor downregulation. Many users run shorter on/off blocks (10-14 on / 7-10 off) per the Selank-style pattern.
Stacking. The natural pair is Semax + Selank: Semax activates and clarifies, Selank calms and stabilizes. Russian clinical use sometimes co-administers them at lower doses (100 mcg Semax + 100-200 mcg Selank intranasal) for mixed cognitive-anxiety presentations — no controlled trial validates the combination specifically, so trial each individually first. For cognitive-decline support, one practitioner’s broader “Unleash Hell” stack pairs Semax with BPC-157 (gut/systemic anti-inflammatory), GHK-Cu (multi-gene cellular repair signal), alpha-GPC (choline precursor), and Cerebrolysin where available.
Side effects & management
Semax is well-tolerated in the published clinical use record. The real-world side-effect cluster:
- Nasal irritation / transient dryness — the most common AE, from the spray vehicle. Usually minor; rotate nostrils, hydrate the nasal mucosa.
- Mild headache at higher doses or first few days; typically resolves.
- Sleep disturbance if dosed too late in the day — Semax is activating. Keep dosing to morning/early afternoon.
- Elevated baseline anxiety in a subset of sensitive users at higher doses — this is the Semax-vs-Selank decision point: if you tend toward anxious/wired baseline, Selank is the better starting tool.
- Transient blood-pressure changes documented in some Russian reports; clinically usually trivial but worth noting if you’re hypertensive.
There’s no documented dependence, tolerance, or withdrawal pattern — Semax is not a stimulant in the pharmacological sense, and the protocol design (4 weeks on / 2 weeks off) reflects receptor-pharmacology caution, not a withdrawal-management concern.
Regulatory status
Russia: Approved by the Russian Ministry of Health for stroke recovery, TBI, and cognitive/vascular disorders. Sold commercially as 0.1% and 1% intranasal solutions. US: Not FDA-approved for any indication. Not a controlled substance. Sold legally as a research chemical, “not for human consumption.” Not on the WADA prohibited list (which is unusual for a peptide of this profile and notable for athletes). NOT available via 503A compounding pharmacies: on September 29, 2023, FDA added Semax (heptapeptide) to its Category 2 bulk-drug-substances list — substances flagged with significant-safety-concern questions, which bars them from 503A compounding. (Selank acetate and DSIP/Emideltide were added in the same action.) So unlike the BPC-157-era “available via compounding” framing, Semax is research-channel-only in the US. This is an active regulatory area tied to the FDA’s pharmacy-compounding advisory agenda.
Technical & analytical reference (chemistry & QC)
Molecular identity verified against PubChem (2026-06-21). Analytical-method detail below is compiled from a third-party technical reference (PeptideBiologix) and tagged where the underlying figure is uncited.
| Field | Value |
|---|---|
| Molecular formula | C37H51N9O10S (PubChem CID 9811102) |
| Average MW | 813.93 g/mol |
| CAS | 80714-61-0 |
| Sequence | MEHFPGP (Met-Glu-His-Phe-Pro-Gly-Pro; ACTH(4-7) + Pro-Gly-Pro tail) |
| HPLC purity criterion | RP-HPLC (C18, 0.1% TFA / acetonitrile) main peak ≥95% (research-grade typically ≥98%) |
| MS identity | ESI-MS [M+2H]²⁺ m/z 407.5, [M+3H]³⁺ m/z 272.0; MALDI-TOF [M+H]⁺ m/z 814.4; mass accuracy ±0.5 Da |
| Counterion / net peptide | TFA salt; TFA content ≤2%; peptide content ≥80% (dry basis); endotoxin <0.5 EU/mg |
| Storage / reconstitution | Lyophilized −20°C/−80°C, sealed, dark (>95% purity ≥24 mo); reconstitute in saline/PBS pH 6.5–7.5, 2–8°C use within 7–14 days; freeze aliquots for longer; intranasal formulations may use benzyl alcohol preservative |
| Degradation / stability | N-terminal methionine oxidation (→ sulfoxide/sulfone); Pro-Gly peptide-bond hydrolysis; deamidation; max stability pH ~4.0–6.0 |
Primary-literature citation leads (PeptideBiologix; confirm before citing): Dolotov et al. Brain Res 2006;1117(1):54-60 (BDNF/trkB upregulation, PMID 16962082); Medvedeva et al. BMC Genomics 2014;15:228 (ischemia transcriptomics, PMID 24666810); Shadrina et al. Mol Biol 2007 (antiparkinsonian, PMID 18163254); Stavchansky et al. J Mol Neurosci 2011 (PMID 20680704); Kaplan et al. 1996 (human nootropic activity)
Sources
- Durst clinical-practice intro, intranasal-as-standard confirmation, Selank-vs-Semax distinction.
- one practitioner mechanism depth, three-failures framework applied to brain, disease applications, 5-peptide stack rationale, Alzheimer’s reframe.
- Semax B/yellow grading.
- cross-reference for the Semax-vs-Selank operational distinction.
- thepeptidelist.com directory entry; source of the now-verified Russian clinical PMIDs (11517472, 29798983, 15792140, 30225715, 32342318, 10741256, 36083821, 12459874) and the FDA-Category-2 (compounding-restricted) status flag.
- Morelli’s 15-min Selank/Semax route comparison. The route-dependent receptor finding extends to Semax per Andreeva et al. 2020 Neurochemical Journal (intranasal Semax → nootropic-predominant; intraperitoneal Semax → anxiolytic-predominant). Detailed treatment lives in the Selank wiki under “Route changes the receptor”; the Semax-relevant slice is in the BBB-crossing paragraph above. ✅ verified 2026-06-22 via Andreeva 2020 (DOI 10.1134/S1819712420030113) + Volkova 2018 (PMID 29787664) anchor papers.
- Holyfield YouTube Short on the practical mechanics of mixing Semax or Selank into a metered-dose nasal spray. Source of the 10 mg vial + 5 mL sterile saline → 200 mcg per spray DIY recipe, the sterile-saline-vs-bacteriostatic-water choice for daily intranasal use, and the boil-the-sprayer first-use sterilization step. Lighter addition to the Real-world protocol section above; full treatment lives in Selank.
- FDA Category 2, Sept 29 2023: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
Related: Selank · Glutathione · the Khavinson cognitive peptides (Pinealon, Cortagen) · BPC-157 · GHK-Cu · MOTS-c.
Sources & references
- Durst clinical-practice intro, intranasal-as-standard confirmation, Selank-vs-Semax distinction.
- one practitioner mechanism depth, three-failures framework applied to brain, disease applications, 5-peptide stack rationale, Alzheimer’s reframe.
- Semax B/yellow grading.
- cross-reference for the Semax-vs-Selank operational distinction.
- thepeptidelist.com directory entry; source of the now-verified Russian clinical PMIDs (11517472, 29798983, 15792140, 30225715, 32342318, 10741256, 36083821, 12459874) and the FDA-Category-2 (compounding-restricted) status flag.
- Morelli’s 15-min Selank/Semax route comparison. The route-dependent receptor finding extends to Semax per Andreeva et al. 2020 Neurochemical Journal (intranasal Semax → nootropic-predominant; intraperitoneal Semax → anxiolytic-predominant). Detailed treatment lives in the Selank wiki under “Route changes the receptor”; the Semax-relevant slice is in the BBB-crossing paragraph above. ✅ verified 2026-06-22 via Andreeva 2020 (DOI 10.1134/S1819712420030113) + Volkova 2018 (PMID 29787664) anchor papers.
- Holyfield YouTube Short on the practical mechanics of mixing Semax or Selank into a metered-dose nasal spray. Source of the 10 mg vial + 5 mL sterile saline → 200 mcg per spray DIY recipe, the sterile-saline-vs-bacteriostatic-water choice for daily intranasal use, and the boil-the-sprayer first-use sterilization step. Lighter addition to the Real-world protocol section above; full treatment lives in Selank.
- FDA Category 2, Sept 29 2023: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
Related: Selank · Glutathione · the Khavinson cognitive peptides (Pinealon, Cortagen) · BPC-157 · GHK-Cu · MOTS-c.
Community experience reports
Anecdotal — real-world reports from the peptide community, not clinical evidence. Presented alongside the graded science above, not as a substitute for it.
Companion raw digest: Evidence tier: throughout Last updated: 2026-07-10 Cross-refs:
[Selank](/peptides/selank/)
Who reports the strongest results
Burned-out knowledge workers, creatives, and anyone experiencing motivational depletion or cognitive fog. Semax’s community reputation is built around two applications: (1) clarity and focus that enables difficult cognitive work without force, and (2) recovery from burnout states where motivation has collapsed.
What the community actually says
The focus experience — how it differs from stimulants
Community positions semax distinctly from amphetamine-class stimulants or modafinil:
- Stimulants force focus through dopamine/norepinephrine activation — you push through cognitive resistance
- Semax removes cognitive resistance — “the cobwebs cleared” rather than “pushed through cobwebs”
- Words and ideas come more readily; attention flows toward difficult tasks rather than requiring forcing
- Described by multiple creative users as “flow state access” rather than “grind mode”
Burnout recovery — the underreported application
Multiple detailed community accounts document semax cycles during recovery from severe burnout:
- Intrinsic motivation returning after extended periods of disengagement
- “Wanted to work again” — the most consistent phrasing in burnout recovery threads
- Not forced productivity — genuine re-engagement with work
BDNF and neuroplasticity
Community discussions frequently reference semax’s proposed BDNF-upregulating mechanism. This drives community interest in using it during high-learning periods (skill acquisition, rehabilitation, recovery).
Protocol as used by the community
Route: Intranasal is strongly preferred — community reasoning is pharmacokinetic (olfactory neuron access, avoids peptide degradation). SubQ and IM also used with good effect.
Dose: 200–600 mcg per dose; 200–300 mcg to start; 600 mcg is the practical ceiling
Timing: Morning or early afternoon only — semax has a stimulating quality that disrupts sleep if taken in the evening
Cycling: 10–14 days on / 7–10 days off is most common
Side effects
| Effect | Pattern |
|---|---|
| Overstimulation / anxiety | At higher doses; the stimulating quality can tip into anxiety |
| Headache | Occasional; initial days or higher doses |
| Sleep disruption | If dosed too late; morning-only timing prevents this |
| Nasal irritation | Mild; common with intranasal |
| Hair loss | Contested; some users report shedding that reversed on stopping; others report none; no controlled data |
The Semax + Selank combination — the community gold standard
Semax (clarity/focus/stimulating) + Selank (anxiety reduction/calm) = “focused calm.” This is the most-discussed cognitive peptide combination and the default recommendation for both peptides.
Rule: do NOT take simultaneously. Alternate dosing (morning/evening or alternate days). Simultaneous use produces a mixed effect that users describe as less clean than the alternating approach.
See [Selank](/peptides/selank/) for the Selank side of the stack.
Cross-references
[Selank](/peptides/selank/)— the standard pairing; anxiety reduction complement to semax’s clarity effect